Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2022

View Archived Issues

JY-201 ADC shows promise for tumors with low HER2 expression

Tarus Therapeutics targets adenosine A2A/A2B receptors with compounds TT-10 and TT-4

ABL-103 demonstrates potent in vitro and vivo antitumor activity

ASN-90, a novel OGA inhibitor with activity in models of tauopathies and alpha-synucleinopathies

CSPC Zhongqi Pharmaceutical Technology patents new ATM inhibitors

Chinese investigators disclose new compounds for COPD

Charles University in Prague synthesizes new TET1 inhibitors

Wigen Biomedicine Technology presents new GTPase KRAS inhibitors

Medshine Discovery synthesizes PRMT5 inhibitors

U.S. DoD supports Aclipse's development of M-102 for ALS

TATX-03 antibody cocktail shows in vitro neutralizing activity toward SARS-CoV-2 Omicron BA.2

Silo Pharma produces SPU-21 liposomes for preclinical study for rheumatoid arthritis

Dual adenosine receptor A2A/A2B antagonist M-1069 reduces tumor growth in vivo

KLS-13019 prevents the development of chemotherapy-induced peripheral neuropathy in rodents

Astrocyte-produced enzyme affects neuronal activity, stroke outcomes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...